Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed attachment file name file name title title grouped question UIN question first answered answering member label
tabling member	label

Search

50445

registered interest
date	09/05/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the beneficial effects on patient wellbeing and rate of recovery of hospital beds overlooking green spaces.
tabling member constituency	Newport West
tabling member printed	Paul Flynn
uin	198308
answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Healthcare facilities should provide a therapeutic environment in which the overall design of the building contributes to the process of healing. In 2013, the Department published design guidance for acute and mental health hospital inpatient settings acknowledging that views outside, together with access to sunshine or direct daylight, have been shown to benefit a patient's recovery. This might include landscaped gardens or a courtyard with good-quality natural planting. Copies of the guidance, <em>Health Building Note 04-01: Adult in-patient facilities</em> and <em>Health Building Note 03-01: Adult Acute Mental Health Units</em>, have been placed in the Library.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb attachment 1 file name PQ198306_8 - Library Doc - Report - Part 1.pdf title Health Building Note 03-01 2 file name PQ198306_8 - Library Doc - Report - Part 2.pdf title Health Building Note 04-01 grouped question UIN 198306 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
tabling member	545 label Biography information for Paul Flynn

50446

registered interest
date	09/05/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what studies his Department has assessed on the treatment of depression and anxiety by increasing access to green spaces in urban areas.
tabling member constituency	Newport West
tabling member printed	Paul Flynn
uin	198306
answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Healthcare facilities should provide a therapeutic environment in which the overall design of the building contributes to the process of healing. In 2013, the Department published design guidance for acute and mental health hospital inpatient settings acknowledging that views outside, together with access to sunshine or direct daylight, have been shown to benefit a patient's recovery. This might include landscaped gardens or a courtyard with good-quality natural planting. Copies of the guidance, <em>Health Building Note 04-01: Adult in-patient facilities</em> and <em>Health Building Note 03-01: Adult Acute Mental Health Units</em>, have been placed in the Library.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb attachment 1 file name PQ198306_8 - Library Doc - Report - Part 1.pdf title Health Building Note 03-01 2 file name PQ198306_8 - Library Doc - Report - Part 2.pdf title Health Building Note 04-01 grouped question UIN 198308 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
tabling member	545 label Biography information for Paul Flynn

50447

registered interest
date	09/05/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 7 May 2014, Official Report, column 244W, on prescriptions: fees and charges, what the cost of administering the exemption arrangements for prescription charges was in each of the last 10 years.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	198340
answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>The following table provides an estimate of direct and overhead costs for the administration of prescription pre-payment, maternity exemption and medical exemption certificates for the latest eight financial years in England. These costs are the only elements of the prescription charging system that can be separately identified for England. Information prior to 2006-07 is not retained by the NHS Business Services Authority.</p><p> </p><p> </p><table><tbody><tr><td colspan="9"><p>NHS prescription charge administrative process from 2006-07 to 2013-14 (£000s)</p></td></tr><tr><td> </td><td><p>2006-07</p></td><td><p>2007-08</p></td><td><p>2008-09</p></td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td><p>Pre-payment <br>Certificates,<br>Maternity exemption <br>certificates,<br>Medical exemption <br>certificates</p></td><td><p>3,318</p></td><td><p>3,807</p></td><td><p>3,889</p></td><td><p>4,586</p></td><td><p>4,480</p></td><td><p>4,941</p></td><td><p>4,988</p></td><td><p>5,366</p></td></tr></tbody></table><p> </p><p><em>Source: </em>NHS Business Services Authority costing model</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
tabling member	534 label Biography information for Chris Ruane

50481

registered interest
date	09/05/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the cost was of translation and interpreter services used by each individual NHS trust in England and Wales in each of the last five years.
tabling member constituency	Bury St Edmunds
tabling member printed	Mr David Ruffley
uin	198333
answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>This information is not held centrally. National Health Service organisations have duties under equality legislation which include making sure that their communities can understand information about NHS services and that patients and clinicians can communicate with each other. However, the Department would encourage NHS organisations to be efficient and save money where possible by working together and sharing resources.</p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
tabling member	133 label Biography information for Mr David Ruffley

50483

registered interest
date	09/05/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what (a) pharmacological treatments and (b) associated indications the National Institute for Health and Care Excellence has recommended for cancer treatment through either single or multiple technology appraisals in (i) 2012, (ii) 2013 and (iii) 2014.
tabling member constituency	Manchester, Withington
tabling member printed	Mr John Leech
uin	198317
answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198318 198319 198324 198325 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
tabling member	1543 label Biography information for Mr John Leech

50484

registered interest
date	09/05/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will publish the determined population size for each pharmacological treatment and associated indications which the National Institute for Health and Care Excellence has (a) recommended for cancer treatment and (b) recommended for cancer treatment under the end-of-life criteria in (i) 2012, (ii) 2013 and (iii) 2014.
tabling member constituency	Manchester, Withington
tabling member printed	Mr John Leech
uin	198325
answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198317 198318 198319 198324 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
tabling member	1543 label Biography information for Mr John Leech

50485

registered interest
date	09/05/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will publish the final calculated cost per quality adjusted life year of each pharmacological treatment and associated indications which the National Institute for Health and Care Excellence has recommended for cancer treatments; and which such treatments and indications have been recommended under the end-of-life criteria in (a) 2012, (b) 2013 and (c) 2014.
tabling member constituency	Manchester, Withington
tabling member printed	Mr John Leech
uin	198318
answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198317 198319 198324 198325 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
tabling member	1543 label Biography information for Mr John Leech

50486

registered interest
date	09/05/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what (a) pharmacological treatments and (b) associated indications the National Institute for Health and Care Excellence has recommended against in (i) 2012, (ii) 2013 and (iii) 2014.
tabling member constituency	Manchester, Withington
tabling member printed	Mr John Leech
uin	198319
answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198317 198318 198324 198325 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
tabling member	1543 label Biography information for Mr John Leech

50487

registered interest
date	09/05/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will publish the final calculated cost per quality adjusted life year of each pharmacological treatment and associated indications which the National Institute for Health and Care Excellence has not recommended for cancer treatment in (a) 2012, (b) 2013 and (c) 2014.
tabling member constituency	Manchester, Withington
tabling member printed	Mr John Leech
uin	198324
answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198317 198318 198319 198325 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
tabling member	1543 label Biography information for Mr John Leech